Chen Wenxin, Guo Yufeng
Department of Pediatric Internal Medicine, The Second People's Hospital of Liaocheng, Liaocheng, Shandong 252600, P.R. China.
Department of Cardiothoracic Surgery, The Second People's Hospital of Liaocheng, Liaocheng, Shandong 252600, P.R. China.
Exp Ther Med. 2019 Jul;18(1):642-646. doi: 10.3892/etm.2019.7586. Epub 2019 May 16.
Clinical efficacy of vitamin K1 combined with meropenem on the treatment of pertussis syndrome was evaluated. Clinical data of 170 children with pertussis syndrome treated in the Second People's Hospital of Liaocheng from March 2015 to March 2017 were collected. Of these, 87 patients who were treated with vitamin K1 combined with meropenem were regarded as the experiment group. A total of 83 patients who were treated with meropenem alone were regarded as the control group. Both groups were treated with anti-infective, respiratory support, antispasmodic, expectorant and other basic treatments. The therapeutic effects, duration of spasmodic cough, length of hospitalization, antipyretic time, duration of voice disappearance and healing time were observed between the two groups. The duration of spasmodic cough and length of hospitalization in the experiment were lower than the control group, and the difference was statistically significant between the groups (P<0.05). The explicit efficiency (51.72%) and total effective efficiency (99.55%) in the experiment group were significantly higher than the explicit efficiency (36.14%) and total effective efficiency (78.31%) in the control group. There was a statistically significant difference between the groups (P<0.05). The voice disappearance time and healing time in the experiment group were significantly shorter than the control group, and there was a statistically significant difference between the groups (P<0.05). The antipyretic time in the experiment group was lower than that of the control group, the difference between the groups was not statistically significant (P>0.05). The treatment with vitamin K1 and meropenem has a significant effect in relieving pediatric pertussis syndrome, it can shorten the duration of spasmodic cough, antipyretic time, duration of voice disappearance and length of hospitalization in children with pertussis syndrome, and improve the efficacy clinically.
评估维生素K1联合美罗培南治疗百日咳综合征的临床疗效。收集2015年3月至2017年3月在聊城市第二人民医院治疗的170例百日咳综合征患儿的临床资料。其中，87例接受维生素K1联合美罗培南治疗的患者作为试验组。83例仅接受美罗培南治疗的患者作为对照组。两组均给予抗感染、呼吸支持、解痉、祛痰等基础治疗。观察两组的治疗效果、痉挛性咳嗽持续时间、住院时间、退热时间、声音消失持续时间和治愈时间。试验组的痉挛性咳嗽持续时间和住院时间低于对照组，组间差异有统计学意义（P<0.05）。试验组的显效率（51.72%）和总有效率（99.55%）显著高于对照组的显效率（36.14%）和总有效率（78.31%）。组间差异有统计学意义（P<0.05）。试验组的声音消失时间和治愈时间明显短于对照组，组间差异有统计学意义（P<0.05）。试验组的退热时间低于对照组，组间差异无统计学意义（P>0.05）。维生素K1与美罗培南联合治疗对缓解小儿百日咳综合征有显著效果，可缩短百日咳综合征患儿的痉挛性咳嗽持续时间、退热时间、声音消失持续时间和住院时间，并提高临床疗效。
